A detailed history of Elevatus Welath Management transactions in Abb Vie Inc. stock. As of the latest transaction made, Elevatus Welath Management holds 1,385 shares of ABBV stock, worth $253,565. This represents 0.09% of its overall portfolio holdings.

Number of Shares
1,385
Previous 10,776 87.15%
Holding current value
$253,565
Previous $1.85 Billion 85.2%
% of portfolio
0.09%
Previous 0.69%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$163.84 - $199.33 $1.54 Million - $1.87 Million
-9,391 Reduced 87.15%
1,385 $274 Million
Q2 2024

Aug 14, 2024

BUY
$154.79 - $180.76 $1.41 Million - $1.64 Million
9,087 Added 538.01%
10,776 $1.85 Billion
Q1 2024

May 10, 2024

SELL
$159.82 - $182.1 $106,440 - $121,278
-666 Reduced 28.28%
1,689 $307 Million
Q4 2023

Feb 12, 2024

BUY
$137.6 - $154.97 $126,316 - $142,262
918 Added 63.88%
2,355 $365 Million
Q3 2023

Nov 14, 2023

BUY
$133.59 - $154.65 $191,968 - $222,232
1,437 New
1,437 $214 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $324B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Elevatus Welath Management Portfolio

Follow Elevatus Welath Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Elevatus Welath Management, based on Form 13F filings with the SEC.

News

Stay updated on Elevatus Welath Management with notifications on news.